New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Air pollutants can affect cardiometabolic health even at low levels, but diet may mitigate the outcomes

Air pollutants can affect cardiometabolic health even at low levels, but diet may mitigate the outcomes

by University of Eastern FinlandCredit:Environmental Research(2023). DOI: 10.1016/j.envres.2023.117637Exposure to air pollutants, even at very low concentrations, was associated with
Cardiovascular Diseases March 23,2024
Air pollutants can affect cardiometabolic health even at low levels, but diet may mitigate the outcomes

Air pollutants can affect cardiometabolic health even at low levels, but diet may mitigate the outcomes

by University of Eastern FinlandCredit:Environmental Research(2023). DOI: 10.1016/j.envres.2023.117637Exposure to air pollutants, even at very low concentrations, was associated with
Cardiovascular Diseases March 23,2024
Patients facing death are opting for a lifesaving heart device—but at what risk?

Patients facing death are opting for a lifesaving heart device—but at what risk?

by Daniel Chang, Holly K. Hacker, KFF Health NewsCredit: CC0 Public DomainToo old and too sick for a heart transplant, Arvid Herrman was given a choice: have a mechanical pump implanted in his heart,
Cardiovascular Diseases March 23,2024
Patients facing death are opting for a lifesaving heart device—but at what risk?

Patients facing death are opting for a lifesaving heart device—but at what risk?

by Daniel Chang, Holly K. Hacker, KFF Health NewsCredit: CC0 Public DomainToo old and too sick for a heart transplant, Arvid Herrman was given a choice: have a mechanical pump implanted in his heart,
Cardiovascular Diseases March 23,2024
Inflammation of the heart muscle following viral infection can impede long-term cardiac function

Inflammation of the heart muscle following viral infection can impede long-term cardiac function

by University of FreiburgCharacteristic stripes (green) make the heart muscle cell (cardiomyocyte) easily recognizable. The virus infection in this cell is shown by viral RNA which has been color
Cardiovascular Diseases March 23,2024
Inflammation of the heart muscle following viral infection can impede long-term cardiac function

Inflammation of the heart muscle following viral infection can impede long-term cardiac function

by University of FreiburgCharacteristic stripes (green) make the heart muscle cell (cardiomyocyte) easily recognizable. The virus infection in this cell is shown by viral RNA which has been color
Cardiovascular Diseases March 23,2024
Going for a walk wasn't really a thing 300 years ago—the Victorians turned it into a popular pastime

Going for a walk wasn't really a thing 300 years ago—the Victorians turned it into a popular pastime

by Lauren Nichola Colley,The ConversationCredit: Pixabay/CC0 Public DomainGoing for a walk is always a good idea. Perhaps, if you are lucky enough, this might be a hike along ragged cliffs or tr
Oncology March 22,2024
Going for a walk wasn't really a thing 300 years ago—the Victorians turned it into a popular pastime

Going for a walk wasn't really a thing 300 years ago—the Victorians turned it into a popular pastime

by Lauren Nichola Colley,The ConversationCredit: Pixabay/CC0 Public DomainGoing for a walk is always a good idea. Perhaps, if you are lucky enough, this might be a hike along ragged cliffs or tr
Oncology March 22,2024
ADHD drug shortages: What to expect if you take Vyvanse and can't access your usual dose

ADHD drug shortages: What to expect if you take Vyvanse and can't access your usual dose

by Alison Poulton,The ConversationCredit: Pixabay/CC0 Public DomainImagine you or your child has attention deficit hyperactivity disorder (ADHD), and after several weeks, or even months, you&#39
Breakthroughs March 22,2024
ADHD drug shortages: What to expect if you take Vyvanse and can't access your usual dose

ADHD drug shortages: What to expect if you take Vyvanse and can't access your usual dose

by Alison Poulton,The ConversationCredit: Pixabay/CC0 Public DomainImagine you or your child has attention deficit hyperactivity disorder (ADHD), and after several weeks, or even months, you&#39
Breakthroughs March 22,2024
Novel treatment regimen for FLT3-mutated acute myeloid leukemia shows promise in new study

Novel treatment regimen for FLT3-mutated acute myeloid leukemia shows promise in new study

by Roswell Park Comprehensive Cancer CenterAcute myelocytic leukemia (AML). Credit: Unsplash/CC0 Public DomainUp to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene
Oncology March 22,2024
Novel treatment regimen for FLT3-mutated acute myeloid leukemia shows promise in new study

Novel treatment regimen for FLT3-mutated acute myeloid leukemia shows promise in new study

by Roswell Park Comprehensive Cancer CenterAcute myelocytic leukemia (AML). Credit: Unsplash/CC0 Public DomainUp to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene
Oncology March 22,2024
'Suspended animation' drug could aid organ transplantation and survival from traumatic injury

'Suspended animation' drug could aid organ transplantation and survival from traumatic injury

by eLifeSNC80 uptake and activity at the delta opioid receptor. a. Distribution of SNC80 in Xenopus tadpoles after 1 and 2 hours of compound exposure. b. Uptake of SNC80 in the tadpole skeletal m
Breakthroughs March 22,2024
'Suspended animation' drug could aid organ transplantation and survival from traumatic injury

'Suspended animation' drug could aid organ transplantation and survival from traumatic injury

by eLifeSNC80 uptake and activity at the delta opioid receptor. a. Distribution of SNC80 in Xenopus tadpoles after 1 and 2 hours of compound exposure. b. Uptake of SNC80 in the tadpole skeletal m
Breakthroughs March 22,2024
PCSK9 inhibitor access remains a significant barrier, leaving patients at risk for heart attacks and strokes

PCSK9 inhibitor access remains a significant barrier, leaving patients at risk for heart attacks and strokes

by Family Heart FoundationCredit: Pixabay/CC0 Public DomainA new study published inCirculation: Cardiovascular Quality and Outcomesfrom the Family Heart Foundation—a patient-centered resea
Cardiovascular Diseases March 22,2024
PCSK9 inhibitor access remains a significant barrier, leaving patients at risk for heart attacks and strokes

PCSK9 inhibitor access remains a significant barrier, leaving patients at risk for heart attacks and strokes

by Family Heart FoundationCredit: Pixabay/CC0 Public DomainA new study published inCirculation: Cardiovascular Quality and Outcomesfrom the Family Heart Foundation—a patient-centered resea
Cardiovascular Diseases March 22,2024
Addition of durvalumab, bevacizumab to TACE beneficial in liver cancer

Addition of durvalumab, bevacizumab to TACE beneficial in liver cancer

by Elana GotkineFor patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) impro
Oncology March 22,2024
Addition of durvalumab, bevacizumab to TACE beneficial in liver cancer

Addition of durvalumab, bevacizumab to TACE beneficial in liver cancer

by Elana GotkineFor patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) impro
Oncology March 22,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com